Condition

Metastatic Prostate Cancer clinical trials and research

• 47Clinical trials
• 26NIH research projects
• 15Countries

Newest Metastatic Prostate Cancer clinical trials

All recruiting trials (47)

• JANX013 and JANX007 combo in advanced prostate cancer

  A first-in-human study will test JANX013 together with JANX007 to see if this combination is safe and tolerable in adults with metastatic castration-resistant prostate cancer.

  Recruiting Phase 1 Janux Therapeutics · Nashville, Tennessee · NCT07813637

• PSMA PET-Staged Progression-Directed Radiotherapy for Limited Prostate Cancer Progression

  A real-world registry tests how well comprehensive progression-directed radiotherapy works for men with metastatic prostate cancer who show a small number of progressing lesions while on systemic therapy.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość, Lublin Voivodeship · NCT07691697

• Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer

  This registry follows men with new, limited metastatic prostate cancer who receive targeted radiotherapy to the prostate and all visible metastases to see how they do over time in real-world care.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość, Lublin Voivodeship · NCT07686016

• PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer

  This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07650240

• First-in-human imaging test of the GRPR-targeted theranostic pair for advanced breast or prostate cancer

  This early feasibility study tests a GRPR-targeted imaging agent for PET and a low-dose radiopharmaceutical for SPECT in adults with advanced breast or prostate cancer to see if it is safe and can image tumors.

  Recruiting Early Phase 1 Integrated Haematology and Oncology Network · Perth, Western Australia · NCT07608848

• Combined treatment approach in metastatic prostate cancer using AZD2265 (FPI-2265) with palacaparib or docetaxel

  This study tests how AZD2265 (FPI-2265) with or without palacaparib or docetaxel works in men with metastatic castration-resistant prostate cancer who have already tried AR pathway inhibitors.

  Recruiting at 3 sites Phase 1/2 AstraZeneca · Duarte, California and 37 other locations · NCT07590934

• GDC-1261 in advanced or metastatic prostate cancer

  This study tests GDC-1261 to see if it is safe and how it behaves in people with advanced or metastatic prostate cancer who have progressed on prior therapy.

  Recruiting at 6 sites Phase 1/2 Genentech, Inc. · Scottsdale, Arizona and 5 other locations · NCT07567846

• First-in-human AZD8359 STEAP2 TCE in metastatic prostate cancer

  A new treatment called AZD8359 is being tested to see if it is safe and possibly helpful for people with metastatic prostate cancer.

  Recruiting at 5 sites Phase 1/2 AstraZeneca · Orlando, Florida and 7 other locations · NCT07529717

• PULSE Registry: Lutetium-177Lu VIP (pluvict?), for patients with metastatic prostate cancer

  This registry will track how lutetium-177Lu vipivotide tetraxetan is used in real-world care for adults with metastatic prostate cancer.

  Recruiting Novartis · Basel · NCT07484269

• Actinium (225Ac) PSMA therapy for castration‑resistant prostate cancer after Lutetium

  This trial will test whether an injectable Actinium-225 PSMA treatment can control advanced prostate cancer in men whose disease progressed after Lutetium‑PSMA therapy.

  Recruiting Phase 1/2 University College, London · London · NCT07414940

• How medicines are managed during targeted radioligand cancer treatment

  This project tracks how pharmacists and nuclear medicine teams manage medications and provide pharmaceutical advice for adults receiving targeted radioligand treatments like Lutathera and Pluvicto.

  Recruiting Hospices Civils de Lyon · Bron and 2 other locations · NCT07389512

• Dapagliflozin added to a next-generation hormonal therapy for metastatic prostate cancer

  This trial tests whether adding dapagliflozin to standard hormonal therapy helps men with metastatic castration-resistant prostate cancer see better cancer control.

  Recruiting at 2 sites Phase 2 The University of Hong Kong · Shanghai and 1 other locations · NCT07310433

• Lutetium (177Lu) vipivotide tetraxetan treatment for men with metastatic prostate cancer in China

  This study will try lutetium (177Lu) vipivotide tetraxetan in men in China with metastatic prostate cancer (both castration-resistant and hormone-sensitive) to see how it is used, how patients do, and how their quality of life changes.

  Recruiting Novartis · Shanghai, Shanghai Municipality · NCT07290270

• Morning versus evening timing of hormone therapy for metastatic breast and prostate cancer

  This pilot will test whether taking hormone-based cancer drugs in the morning or in the evening works better for people with metastatic breast or prostate cancer.

  Recruiting at 2 sites Phase 4 Ottawa Hospital Research Institute · Kitchener, Ontario and 2 other locations · NCT07252726

• Low Dose Naltrexone to See if Fatigue Improves for Men with Prostate Cancer on Hormone Therapy

  A small daily dose of naltrexone is being tested to see if it helps reduce fatigue in men with metastatic prostate cancer who are on hormone therapy.

  Recruiting Phase 2 University of Arkansas · Little Rock, Arkansas · NCT07224009

• Reducing doctor and patient barriers to genomic (NGS) testing for metastatic prostate cancer

  This project will try two approaches—supporting doctors and supporting patients—to increase genomic (NGS) testing for men with metastatic prostate cancer at Johns Hopkins.

  Recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT07209176

• AZD0516 alone and with AZD9574 for metastatic prostate cancer

  This trial will test AZD0516, alone and combined with AZD9574, to see if it is safe and helps people with metastatic prostate cancer who have castrate-level testosterone.

  Recruiting at 23 sites Phase 1/2 AstraZeneca · Fayetteville, Arkansas and 51 other locations · NCT07181161

• Combining Lutetium-177 PSMA targeted therapy with liver-directed treatment for prostate cancer spread to the liver

  This trial tests whether giving Lutetium-177 PSMA targeted radiation together with liver-directed treatments helps men with metastatic castration‑resistant prostate cancer that has spread to the liver and who progressed on prior androgen pathway inhibitors.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT07145177

• Tarlatamab for DLL3-positive metastatic prostate cancer

  This study will try tarlatamab in adults with metastatic, DLL3-positive prostate cancer that has relapsed or not responded to previous treatments.

  Recruiting at 10 sites Phase 2 Memorial Sloan Kettering Cancer Center · San Diego, California and 9 other locations · NCT07111507

• Home-based telerehabilitation for rural men on hormone therapy for metastatic prostate cancer

  This trial tests whether a home telerehabilitation program helps men in rural areas receiving androgen deprivation therapy for metastatic prostate cancer feel and function better than home exercise without the technology.

  Recruiting University of Utah · Salt Lake City, Utah · NCT07032584

• Developing a liquid biopsy test for advanced prostate cancer

  This study is testing a new blood test for advanced prostate cancer to see if it can help doctors make better treatment decisions by analyzing different genetic information.

  Recruiting at 4 sites Santa Chiara Hospital · Meldola, Forlì-Cesena and 3 other locations · NCT06981377

• Comparing methods to capture circulating tumor cells in metastatic breast or prostate cancer

  This one-day test will compare three blood-based methods (CellSearch®, Parsortix®, and SmartCatch®) to see which best finds circulating tumor cells in people with metastatic breast or prostate cancer before they start a new line of treatment.

  Recruiting Institut Claudius Regaud · Toulouse · NCT06904625

• Prostate cryoablation plus low-dose cyclophosphamide with hormonal therapy for metastatic prostate cancer

  This trial will test whether adding prostate cryoablation and continuous low-dose cyclophosphamide to standard hormone therapy with a modern androgen receptor blocker helps men with newly diagnosed metastatic prostate cancer live longer without PSA progression.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06854250

• Testing HLD-0915 for advanced prostate cancer

  This study is testing a new oral medication called HLD-0915 to see if it can help men with advanced prostate cancer that hasn't responded to other treatments.

  Recruiting at 18 sites Phase 1/2 Janssen Research & Development, LLC · Colorado Springs, Colorado and 17 other locations · NCT06800313

• Cabazitaxel (with or without carboplatin) versus 177Lu-PSMA-617 for PSMA-positive metastatic castration-resistant prostate cancer

  This trial will try whether cabazitaxel (with or without carboplatin) or the PSMA-targeted radioligand 177Lu-PSMA-617 works better for people with PSMA-positive metastatic castration-resistant prostate cancer who have progressed after hormonal therapy.

  Recruiting Phase 2 Case Comprehensive Cancer Center · Cleveland, Ohio · NCT06738303

• Using 18F-Fluciclovine PET/CT to Predict Outcomes of Prostate Cancer Therapy

  This study is testing if special imaging can help predict how well a new prostate cancer treatment works for patients with advanced disease.

  Recruiting Phase 4 VA Greater Los Angeles Healthcare System · Los Angeles, California · NCT06706921

• Combining TURP with standard therapy for metastatic prostate cancer

  This study is testing if combining a procedure to relieve urinary blockage with standard cancer treatments can help men with metastatic prostate cancer live longer and feel better.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06655259

• Targeting gut bacteria to improve prostate cancer treatment

  This study is testing if adding a gut bacteria-targeting medication to standard prostate cancer treatment can help men with advanced prostate cancer respond better to their therapy.

  Recruiting Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT06616597

• Combination of talazoparib and enzalutamide for advanced prostate cancer after abiraterone

  This study is testing if combining two drugs, talazoparib and enzalutamide, can help men with advanced prostate cancer that has worsened after using abiraterone.

  Recruiting at 15 sites Phase 2 Fundacion Oncosur · Bordeaux and 18 other locations · NCT06582628

• Combining carboplatin with docetaxel for advanced prostate cancer treatment

  This study is testing if adding carboplatin to the usual treatment of docetaxel can help people with advanced prostate cancer by slowing down the growth or spread of their disease.

  Recruiting at 14 sites Phase 3 Canadian Cancer Trials Group · Calgary, Alberta and 13 other locations · NCT06439225

• Home-based exercise programs for men with metastatic prostate cancer

  This study is testing two different home exercise programs to see if they can help men with metastatic prostate cancer feel better while starting their treatment.

  Recruiting University of Virginia · Charlottesville, Virginia · NCT06429813

• Combining surgery with hormone therapy for advanced prostate cancer

  This study is testing if combining surgery with hormone therapy and possibly chemotherapy can help men with advanced prostate cancer live longer without their cancer getting worse.

  Recruiting Phase 3 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06350825

• Evaluating AZD0754 for metastatic prostate cancer

  This study is testing a new CAR T-cell therapy called AZD0754 to see if it can safely help people with metastatic prostate cancer.

  Recruiting at 10 sites Phase 1/2 AstraZeneca · Duarte, California and 14 other locations · NCT06267729

• Intermittent treatment with darolutamide for metastatic prostate cancer

  This study is testing if taking darolutamide in cycles, instead of all the time, can help men with advanced prostate cancer feel better while using other treatments.

  Recruiting Phase 3 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06177015

• Using creatine and resistance training to help maintain muscle mass in prostate cancer patients

  This study tests whether taking creatine and doing resistance training can help men with prostate cancer keep their muscle mass and feel better over a year.

  Recruiting Phase 3 University of Utah · Salt Lake City, Utah · NCT06112990

• Detecting low PSMA prostate cancer using a special PET scan

  This study is testing a new type of PET scan to see if it can better detect advanced prostate cancer that has low PSMA levels or neuroendocrine features in patients.

  Recruiting at 2 sites Phase 1 Brigham and Women's Hospital · Boston, Massachusetts and 1 other locations · NCT06062745

• Exercise program to improve health in men with metastatic prostate cancer

  This study is testing whether a 16-week exercise program can help men with metastatic prostate cancer feel stronger and healthier while they are receiving treatment.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT06040125

• Comparing two treatments for metastatic hormone-sensitive prostate cancer

  This study is testing if adding chemotherapy to a hormone treatment can help men with advanced prostate cancer live longer compared to just using hormone treatment alone.

  Recruiting Phase 3 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT05983783

• Evaluating the effects of radiotherapy on patients with oligometastatic cancer

  This study is testing how well Stereotactic Ablative Radiotherapy (SABR) works for people with oligometastatic cancer to see if it can help them live longer and feel better.

  Recruiting Institut Investigacio Sanitaria Pere Virgili · Albacete, Albacete and 20 other locations · NCT05933876

• Exploring liquid biopsy genomic profiling for metastatic prostate cancer in Spain

  This study is testing how analyzing blood and tumor samples can help doctors find better treatment options for men with advanced prostate cancer in Spain.

  Recruiting SOLTI Breast Cancer Research Group · Barcelona · NCT05885009

• Evaluating a new treatment for advanced prostate cancer

  This study is testing a new treatment for advanced prostate cancer to see how safe it is and if it helps patients feel better.

  Recruiting at 26 sites Phase 1 Genentech, Inc. · Scottsdale, Arizona and 25 other locations · NCT05800665

• Impact of Exercise and Statins on Cancer Treatment

  This study is testing if doing supervised exercise while taking cancer drugs helps people with metastatic breast, kidney, ovarian, and prostate cancer feel better and respond better to their treatment compared to exercising on their own, and if adding a cholesterol-lowering medication can make it even more effective.

  Recruiting Phase 3 Tampere University Hospital · Tampere, Länsi-Suomi · NCT05796973

• Supportive care for older men with metastatic prostate cancer

  This study is testing whether a special care plan and remote symptom tracking can help older men with advanced prostate cancer feel better when starting or changing their hormone treatments.

  Recruiting at 3 sites University Health Network, Toronto · Toronto, Ontario and 2 other locations · NCT05582772

• Testing ORIC-944 for metastatic prostate cancer treatment

  This study is testing a new drug called ORIC-944 to see if it can safely help people with metastatic prostate cancer, both on its own and when combined with other treatments.

  Recruiting at 23 sites Phase 1 ORIC Pharmaceuticals · Colorado Springs, Colorado and 26 other locations · NCT05413421

• Investigating a new treatment approach for metastatic prostate cancer

  This study is testing if adding a new drug to regular radiation and hormone therapy can help men with metastatic prostate cancer feel better and live longer.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario and 1 other locations · NCT05404139

• High dose testosterone treatment for certain prostate cancers

  This study is testing whether high doses of testosterone can help men with advanced prostate cancer that has certain genetic changes feel better and manage their disease.

  Recruiting at 16 sites Phase 2 VA Office of Research and Development · Aurora, Colorado and 16 other locations · NCT05011383

• Collecting blood samples from prostate cancer patients

  This study is collecting blood samples from men with prostate cancer to see if genetic differences affect how the disease progresses.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT00923221

NIH-funded research (26)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Combination immunotherapy with radioligand therapy for metastatic prostate cancer

  A study aims to help men with advanced prostate cancer by combining immune therapy with targeted radiation to boost the body’s own defense against cancer.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11415135

• Understanding what drives lethal metastatic prostate cancer in men

  This grant looks at why some prostate cancers become deadly and spread, using patient-derived cells and mouse models.

  NIH research University of Nebraska Medical Center · Omaha, United States · NIH-11411456

• Off-the-shelf tumor cell vaccine tailored to your tumor’s HLA type for advanced prostate cancer

  A new vaccine approach uses donor cancer cells matched to a patient’s immune system to help fight advanced prostate cancer.

  NIH research Briacell Therapeutics Corp · Philadelphia, United States · NIH-11398997

• ASH1L’s role in metastatic prostate cancer and its immune environment

  Aims to understand how the ASH1L gene helps prostate cancer spread and how it shapes the immune environment in bone metastases so future therapies can target this process.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11396556

• Molecular drivers of lineage changes and new therapies for metastatic prostate cancer

  A multi-year study at a major university will explore how metastatic prostate cancer changes its cell type and how to target those changes to help patients.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11389345

• How gut bacteria may affect prostate cancer therapy and resistance

  A new study looks at how gut bacteria make compounds that influence prostate cancer treatments and may drive resistance to therapy.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11361092

• Blood test to detect resistance to hormone therapy in advanced prostate cancer

  This project tests a new blood-based DNA test to spot early resistance to androgen (hormone) therapies in men with advanced prostate cancer.

  NIH research Washington University · Saint Louis, United States · NIH-11231709

• How the ASH1L gene helps prostate cancer spread to bone and evade the immune system

  This project will test whether targeting the ASH1L protein can stop prostate cancer from spreading to bone and help the immune system fight tumors in people with metastatic prostate cancer.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11194264

• Off-the-shelf HLA-matched vaccine for advanced metastatic prostate cancer

  This project develops an off-the-shelf vaccine matched to patients' HLA types to boost immune responses against advanced metastatic prostate cancer.

  NIH research Briacell Therapeutics Corp · Philadelphia, United States · NIH-11184668

• Combining targeted radioligand therapy with immunotherapy for advanced prostate cancer

  Seeing if adding targeted radioligand therapy to immunotherapy helps men with metastatic castration-resistant prostate cancer by boosting the immune attack on tumors.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11181251

• Using neutrophils to overcome hormone therapy resistance in prostate cancer that has spread to bone

  This project will test whether restoring neutrophil (PMN) immune activity can help men with prostate cancer in the bones respond better to androgen-deprivation (hormone-blocking) therapy.

  NIH research University of Nebraska Medical Center · Omaha, United States · NIH-11160637

• How Gut Bacteria Influence Prostate Cancer Treatment

  This project explores how bacteria in the gut might make prostate cancer treatments less effective for men with advanced disease.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11124826

• Personalized Treatment for Metastatic Prostate Cancer Using Blood Samples

  This research aims to find better, personalized treatments for metastatic prostate cancer by looking at cancer cells in a patient's blood.

  NIH research Thomas Jefferson University · Philadelphia, United States · NIH-11099957

• A new blood test for advanced prostate cancer

  This project aims to develop a new blood test to help doctors quickly identify when prostate cancer is becoming resistant to treatment.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11087719

• Monitoring prostate cancer using blood tests and imaging techniques

  This study is looking at new ways to keep an eye on advanced prostate cancer by using blood tests and special imaging techniques, which could help doctors tailor treatments just for you without needing more invasive procedures.

  NIH research University of Southern California · Los Angeles, UNITED STATES · NIH-11015787

• New blood test to detect treatment resistance in advanced prostate cancer

  This study is testing a new blood test called EnhanceAR-Seq that helps find out if metastatic prostate cancer is not responding to treatments earlier than current methods, so patients can get the right care sooner.

  NIH research Washington University · Saint Louis, United States · NIH-10995319

• Understanding how gut bacteria affect prostate cancer treatment resistance

  This study is looking at how the bacteria in your gut might affect how well treatments work for metastatic prostate cancer, and it’s for patients who are currently receiving these therapies.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-10981242

• Examining how circulating tumor cells contribute to racial differences in metastatic prostate cancer

  This study is looking at why Black men are more likely to have advanced prostate cancer than white men by examining special cancer cells in their blood, which could help find better treatments for them.

  NIH research Thomas Jefferson University · Philadelphia, United States · NIH-10953253

• Investigating how fat cells affect prostate cancer spread to bones

  This study is looking at how fat cells in the bone marrow affect prostate cancer that has spread to the bones, with the goal of finding new ways to help patients by understanding how these fat cells help cancer cells survive and resist treatment.

  NIH research Wayne State University · Detroit, United States · NIH-10912506

• Understanding how immune responses can help treat resistant prostate cancer

  This study is looking at how certain immune cells in the blood of men with advanced prostate cancer respond to the disease, especially in the bones, to understand how their function changes over time and how treatment affects them, with the goal of finding better ways to fight the cancer.

  NIH research University of Nebraska Medical Center · Omaha, United States · NIH-10897051

• Understanding what causes aggressive metastatic prostate cancer

  This study is looking at how certain genes might cause slow-growing prostate cancer to become more aggressive and spread, with the hope of finding new treatments to help patients with advanced prostate cancer.

  NIH research University of Nebraska Medical Center · Omaha, United States · NIH-10891541

• Investigating how a specific protein affects metastatic prostate cancer

  This study is looking at a protein called ASH1L to see how it affects the spread of metastatic prostate cancer, with the hope of finding new ways to treat patients facing this challenge.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-10879288

• How fat cells influence the survival of prostate cancer in bones

  This study is looking at how prostate cancer cells interact with fat cells in the bones to see how these interactions might help the cancer grow and resist treatment, with the hope of finding new ways to fight metastatic prostate cancer.

  NIH research Wayne State University · Detroit, United States · NIH-10853121

• Analyzing tumor cells in blood to improve treatment for advanced prostate cancer

  This study is looking at new ways to analyze cancer cells in the blood of men with hard-to-treat prostate cancer, so doctors can better tailor treatments to each patient's needs as the cancer changes over time.

  NIH research Thomas Jefferson University · Philadelphia, United States · NIH-10843884

• Investigating how certain immune cells interact with prostate cancer in the bone.

  This study is looking at how special immune cells can be changed to better fight prostate cancer that has spread to the bones, and it’s testing a drug to help make these immune cells even more effective, all with the goal of finding better treatments for patients with advanced prostate cancer.

  NIH research H. Lee Moffitt Cancer Ctr & Res Inst · Tampa, United States · NIH-10798138

• Investigating how androgen signaling affects prostate cancer growth and treatment.

  This study is looking at how certain molecules in the body affect the growth of advanced prostate cancer that doesn't respond to usual treatments, with the hope of finding new ways to help patients feel better and live longer.

  NIH research Cleveland State University · Cleveland, United States · NIH-10201013

Related topics

Quick answers

How many Metastatic Prostate Cancer clinical trials are recruiting right now?

47, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 15 countries. The most sites are in United States (24 trials), China (8 trials), Spain (8 trials), United Kingdom (7 trials), Australia (7 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 11, Phase 1/2: 7, Phase 3: 6, Phase 1: 5. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →